Skip to content
ClinCalc Pro
Menu
Erythropoiesis-stimulating agent

Epoetin beta

Brand names: NeoRecormon

Epoetin beta is a recombinant human erythropoietin (an erythropoiesis-stimulating agent) used to treat anaemia of chronic kidney disease and certain other anaemias.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

As an analogue of endogenous erythropoietin, it binds erythropoietin receptors on bone marrow erythroid progenitors, promoting red cell production.

Prescribing in practice

  • Avoid overcorrecting haemoglobin, as targeting normal or high levels raises the risk of thromboembolic and cardiovascular events; use the lowest level that avoids transfusion.
  • Correct functional or absolute iron deficiency and ensure adequate folate and B12 to support an effective response.
  • Monitor for new or worsening hypertension, which may require dose adjustment or antihypertensive treatment.

Monitoring

Monitor haemoglobin, blood pressure and iron status regularly, titrating the dose to maintain the target haemoglobin range.

Counselling the patient

  • Keep appointments for blood monitoring so dosing stays in the safe range.
  • Report severe headache, visual symptoms or possible clot symptoms without delay.
  • Continue any prescribed iron supplementation as advised.

Evidence & guidelines

NICE recommends erythropoiesis-stimulating agents for anaemia of chronic kidney disease, emphasising conservative haemoglobin targets.

Reference: NICE TA323; KDIGO 2012 anaemia guideline; BSH; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.